transactions worth over $282 billion in asset and transaction value. RNA assists life sciences and healthcare technology companies and investors by providing research, analysis and consulting support for highly strategic transactions, acquisitions, and commercial partnerships. RNA Advisors' clients include private venture-backed and public companies in biotech, biopharmaceuticals, digital health, medical devices, healthcare services and technology, as well as royalty stream investors, potential joint venturers, M&A transaction counterparties, financiers and licensors/licensees. RNA’s deeply experienced team includes 20+ consultants and analysts delivering high-level to deep-dive market assessments, market research, comparative valuation analyses, and financial modeling and forecasts which support decision making around corporate growth strategies. RNA Advisors also delivers end-to-end transaction support in the form of fairness opinions, intellectual property valuations, asset and enterprise valuations, drug royalty forecasts, derivative security valuations, pro forma capitalization table modeling, and gift/estate tax valuations for investors. Learn more about RNA Advisor client success stories at rnaadvisors.com.